Vivek Subbiah: ESMO24 and an AACR debate is at Healthcare Unfiltered podcast
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X by Chadi Nabhan, the Chief Medical Officer and Head of Strategy at Ryght, adding:
“Such a delight to join the one and only Chadi Nabhan for the Healthcare Unfiltered podcast. We discuss ESMO24 and an AACR AI debate. Enjoy the Viveks Takes podcast this Thanksgiving week!”
Quoting Chadi Nabhan’s post below:
“It’s here . Another installment of VIVEK’s TAKES exclusively on Healthcare Unfiltered and this time, he shares his observations of ESMO24 as well as the infamous AACR debate from October. He says he won the debate.
Listen to Vivek Subbiah here.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023